Welcome to our dedicated page for Accuray Incorp news (Ticker: ARAY), a resource for investors and traders seeking the latest updates and insights on Accuray Incorp stock.
Accuray Incorporated (NASDAQ: ARAY) pioneers precision radiation therapy systems that redefine cancer treatment standards. This dedicated news hub provides investors and healthcare professionals with timely updates on corporate developments, clinical advancements, and strategic initiatives shaping the future of radiation oncology.
Track all essential updates in one place, including earnings announcements, regulatory milestones, and technological breakthroughs related to flagship platforms like CyberKnife and Radixact. Our curated feed simplifies monitoring of partnership agreements, research collaborations, and market expansion efforts critical to understanding Accuray's position in medical technology.
Discover comprehensive coverage of operational updates, leadership changes, and product enhancements that impact clinical workflows and patient outcomes. The resource is designed to help stakeholders assess Accuray's progress in developing adaptive radiotherapy solutions with real-time tumor tracking capabilities.
Bookmark this page for streamlined access to verified information about ARAY, including innovation roadmaps and quality control certifications. Check regularly for objective reporting on developments influencing radiation oncology practices worldwide.
Accuray announced that its customers secured the top two spots in the MArkerless Lung Target Tracking CHallenge (MATCH) using the Synchrony technology on the Radixact and CyberKnife systems. The challenge evaluated the accuracy of tumor-tracking algorithms, with scoring based on radiation therapy system precision. Accuray's technology allows real-time adaptation of treatment based on patient movement, improving treatment accuracy and patient comfort. The results demonstrate Synchrony's potential to enhance lung cancer therapy, offering a non-invasive option for medically inoperable patients.
Accuray Incorporated (NASDAQ: ARAY) reported Q3 fiscal 2021 results, with net revenue of $102.6 million, up from $99.5 million year-over-year. System revenue in China amounted to $24.9 million, while gross orders were $87.4 million, a 16% increase from Q2. However, net loss stood at $0.4 million, a substantial decline from a net income of $2.6 million in the same quarter last year. The company also received regulatory approval for its ClearRT™ Helical kVCT Imaging in Japan. Cash reserves increased to $130.1 million.
Accuray Incorporated (NASDAQ: ARAY) has announced that its ClearRT helical fan-beam kVCT imaging system has been in clinical use for over two months, demonstrating significant potential in radiation oncology. The first patient treatments at Willis-Knighton Cancer Center show enhanced imaging quality, allowing for superior tumor visualization and treatment precision. ClearRT has received Shonin approval in Japan and FDA 510(k) clearance, with a CE Mark expected by the end of June 2021, expanding its market accessibility. The first commercial ClearRT systems have been shipped as scheduled.
Accuray Incorporated (NASDAQ: ARAY) will release its third-quarter financial results for fiscal year 2021, ending March 31, 2021, on April 27, 2021, post-market. The management will hold a conference call at 1:30 p.m. PT (4:30 p.m. ET) to discuss the results. Dial-in numbers are provided for participants, and a live webcast will be available through the company's Investor Relations website. Accuray focuses on innovative radiation therapy solutions aimed at enhancing patient care.
Accuray Incorporated (NASDAQ: ARAY) will participate in the Cowen Annual Health Care Conference on March 2, 2021, at 11:50 AM Pacific. The event is an invitation-only conference connecting over 325 health care companies with institutional investors, focusing on investment opportunities and sector trends. A live webcast of the Fireside Chat will be available on Accuray's website. Accuray is dedicated to innovating radiation therapy solutions to improve patient outcomes across oncology and neuro-radiosurgery.
Accuray Incorporated (NASDAQ: ARAY) has appointed Byron C. Scott, M.D., MBA, to its Board of Directors as of February 12, 2021. Dr. Scott is a renowned physician executive with extensive experience in healthcare analytics and technology. Currently, he teaches at the University of Massachusetts and Jefferson University. His previous roles include Deputy Chief Health Officer at IBM Watson Health and leadership positions at Truven Health Analytics and EmCare. The appointment aims to strengthen Accuray's management team amid evolving radiation therapy market demands.
Accuray Incorporated (NASDAQ: ARAY) will participate in BTIG's Virtual MedTech Conference on February 18 at 12:30 PM Pacific time. The management team will engage in a Fireside Chat, which can be accessed live via the Accuray website. This event aims to connect more than 100 corporate management teams with institutional investors to discuss investment opportunities and sector trends in the healthcare space. Accuray is dedicated to improving lives through advanced radiation therapy solutions.
Accuray Incorporated (NASDAQ: ARAY) reported its fiscal Q2 2021 results, with net revenue of $97.5 million, slightly down from $98.8 million year-over-year. The company achieved gross orders of $75.4 million, increasing backlog by 11% to $596.2 million. GAAP net income was $4.8 million or $0.05 per share, a decline from $10.7 million in the prior year due to a non-cash gain. Adjusted EBITDA rose to $13.5 million from $7.1 million. The company did not provide fiscal 2021 guidance due to COVID-19 uncertainties.
Accuray Incorporated (NASDAQ: ARAY) announced promising results from a phase II trial involving 338 women with low-risk breast cancer. Seven years after receiving once-daily accelerated partial breast irradiation (APBI) with the TomoTherapy System, 98.8% achieved local disease control. The study, published in the International Journal of Radiation Oncology*Biology*Physics, found minimal acute and late toxicities. Key findings include 99.4% ipsilateral breast tumor recurrence-free control at 76 months and excellent patient-reported outcomes regarding breast appearance.
Accuray Incorporated (NASDAQ: ARAY) will announce its financial results for the second quarter of fiscal year 2021, ending December 31, 2020, on January 27, 2021, after market close. A conference call is scheduled for the same day at 1:30 p.m. PT / 4:30 p.m. ET to discuss these results. Investors can participate via dial-in or listen to a live webcast available on the Company's Investor Relations website. A replay of the call will also be accessible for one week following the event.
FAQ
What is the current stock price of Accuray Incorp (ARAY)?
What is the market cap of Accuray Incorp (ARAY)?
